FindTrial
Sign In

CI-581a

DRUG6 trials

Sponsors

New York State Psychiatric Institute

Conditions

Alcohol DependenceAlcohol Use DisorderCannabis DependenceCocaine DependenceCocaine Use DisorderCognitive DysfunctionDepressive SymptomsPost-acute Sequelae of COVID-19

Phase 1

Facilitating the Behavioral Treatment of Cannabis Use Disorder
CompletedNCT02946489
New York State Psychiatric InstituteCannabis Dependence
Start: 2016-10-31End: 2018-08-31Updated: 2020-02-11

Phase 2

Glutamatergic Modulation of Disordered Alcohol Use
CompletedNCT02539511
New York State Psychiatric InstituteAlcohol Dependence
Start: 2015-07-31End: 2017-12-31Updated: 2020-02-11
The Effect of Glutamatergic Modulation on Cocaine Self-administration
CompletedNCT02596022
New York State Psychiatric InstituteCocaine Dependence
Start: 2013-06-30End: 2015-07-31Updated: 2018-06-15
The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking
NCT04084860
New York State Psychiatric InstituteAlcohol Use Disorder
Start: 2019-11-08End: 2024-08-31Target: 120Updated: 2023-11-07
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
Active, not recruitingNCT05690503
New York State Psychiatric InstituteCognitive Dysfunction, Depressive Symptoms, Post-acute Sequelae of COVID-19
Start: 2023-03-20End: 2025-12-31Target: 12Updated: 2024-07-16

Phase 3

Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders
SuspendedNCT03344419
New York State Psychiatric InstituteCocaine Use Disorder
Start: 2017-10-01End: 2024-12-31Target: 150Updated: 2024-07-16